Delcath Liver Chemotherapy Delivery System PMA Anticipated In 2003
This article was originally published in The Gray Sheet
Delcath Systems, Inc. appears on track to submit a premarket approval application to FDA for its Delcath liver chemotherapy drug delivery system in 2003. A pivotal Phase III trial is scheduled to begin in the current quarter.
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.